본문으로 건너뛰기
← 뒤로

Overcoming colorectal cancer and cancer stem cell resistance with photodynamic therapy: new frontiers in oncology.

1/5 보강
RSC advances 2025 Vol.15(45) p. 37833-37855
Retraction 확인
출처

Zahra M, Zahra UB, Abrahamse H, George BP

📝 환자 설명용 한 줄

Colorectal cancer (CRC) is a major global health issue characterized by abnormal cell growth leading to high morbidity and mortality rates.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Zahra M, Zahra UB, et al. (2025). Overcoming colorectal cancer and cancer stem cell resistance with photodynamic therapy: new frontiers in oncology.. RSC advances, 15(45), 37833-37855. https://doi.org/10.1039/d5ra07380d
MLA Zahra M, et al.. "Overcoming colorectal cancer and cancer stem cell resistance with photodynamic therapy: new frontiers in oncology.." RSC advances, vol. 15, no. 45, 2025, pp. 37833-37855.
PMID 41080691
DOI 10.1039/d5ra07380d

Abstract

Colorectal cancer (CRC) is a major global health issue characterized by abnormal cell growth leading to high morbidity and mortality rates. While conventional treatments like chemotherapy and surgery exist, they often fall short due to severe side effects and the emergence of treatment resistance, particularly from cancer stem cells (CSCs). These CSCs contribute to tumor initiation, progression, and recurrence, posing challenges for effective management. Photodynamic therapy (PDT) offers a promising alternative, leveraging light-activated photosensitizers (PSs) to selectively target and destroy tumor cells while minimizing damage to healthy tissue. Recent advancements in PDT, including the use of nanoparticles (NPs) and novel PSs, enhance its efficacy against CRC and CSCs. Preclinical studies have demonstrated PDT ability to induce apoptosis and inhibit tumor growth in various models, highlighting its potential as a therapeutic strategy. Additionally, combining PDT with immune checkpoint inhibitors may further improve treatment outcomes by activating robust immune responses. This review discusses the mechanisms of resistance in CRC, the role of CSCs, and the evolving landscape of PDT, emphasizing the need for continued research to optimize combination therapies for enhanced efficacy against colorectal cancer.

같은 제1저자의 인용 많은 논문 (3)